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The following inclusion criteria must be met for individuals to be eligible for the study.  
1. Subject has signed an ICF prior to any study-specific procedures being 
performed.  
2. Subject is an ambulatory male or female between 18 and 65 years of age, 
inclusive.  
3. Subject is in good physical health and has no clinically significant findings, as 
determined by the Investigator, on physical examination, 12-lead ECG, or clinical 
laboratory tests.  
4. Subject agrees to adhere to the study requirements.  
5. Subject has a diagnosis of MDD that has been present for at least a 4-week 
period as diagnosed by Structured Clinical Interview for Diagnostic and Statistical 
Manual of Mental Disorders, Fifth Edition (DSM-5) Axis I Disorders (SCID-I).  
6. Subject has a HAM-D total score of ≥22 at screening and Day 1 (prior to 
dosing).  
7. Removed per Amendment #2.  
8. Subject is willing to delay start of other antidepressant or antianxiety 
medications and any new pharmacotherapy regimens, including as-needed 
benzodiazepine anxiolytics, during the screening and treatment periods.  
9. Female subject agrees to use one of the following methods of contraception 
during participation in the study and for 30 days following the last dose of study 
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drug, unless they are postmenopausal (defined as no menses for 12 months 
without an alternative medical cause) and/or surgically sterile:  
• Combined (estrogen and progestogen containing) oral, intravaginal, or 
transdermal hormonal contraception associated with inhibition of ovulation.  
• Oral, injectable, or implantable progestogen-only hormonal contraception 
associated with inhibition of ovulation.  
• Intrauterine device.  
• Intrauterine hormone-releasing system.  
• Bilateral tubal occlusion. 
• Vasectomized partner.  
• Sexual abstinence (no sexual intercourse).  
Exclusion criteria: 
 
Subjects will be excluded if they meet any of the following exclusion criteria:  
1. Subject has a history of suicide attempt.  
2. Subject has a recent history or active clinically significant manifestations of 
metabolic, hepatic, renal, hematological, pulmonary, cardiovascular, 
gastrointestinal, musculoskeletal, dermatological, urogenital, neurological, or 
eyes, ears, nose, and throat disorders, or any other acute or chronic condition 
that, in the Investigator's opinion, would limit the subject's ability to complete or 
participate in this clinical study.  
3. Subject has a history of treatment-resistant depression, defined as persistent 
depressive symptoms despite treatment with adequate doses of antidepressants 
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from two different classes for an adequate amount of time (ie, at least 4 weeks of 
treatment).  
4. Subject has a known allergy to SAGE-217, allopregnanolone, or related 
compounds.  
5. Subject has a positive pregnancy test at screening or on Day 1 prior to the 
start of study drug administration.  
6. Subject has detectable hepatitis B surface antigen (HBsAg), anti-hepatitis C 
virus (HCV), or human immunodeficiency virus (HIV) antibody at screening 
(except if the subject has a documented Hepatitis C antigen test (HCV RNA) with 
a negative result in their recent medical history).  
7. Subject has active psychosis per Investigator assessment.  
8. Subject has a medical history of seizures.  
9. Subject has a medical history of bipolar disorder, schizophrenia, and/or 
schizoaffective disorder.  
10. Subject has a history of alcohol or drug dependence (including 
benzodiazepines) in the 12 months prior to screening.  
11. Subject has had exposure to another investigational medication or device 
within 30 days prior to screening.  
12. Subject has been treated or randomized in this study (eg, Part A) or any 
other study employing SAGE-217 previously (ie, subject may not have received 
study drug and then re-enroll).  
13. Subject has had administration of psychotropics that have been initiated 
within 14 days prior to screening and/or are not being taken at a stable dose in 
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Part A. Subject has had administration of psychotropic medications that are used 
with the intent to treat depressive symptoms such as antidepressants, atypical 
antipsychotics, etc., which have been initiated within 30 days prior to screening 
and/or are not being taken at a stable dose in Part B.  
14. Use of any known strong inhibitors and/or inducers of CYP3A4 within the 14 
days or five half-lives (whichever is longer) or consumed grapefruit juice, 
grapefruit, Seville oranges, or St. John's Wort or products containing these within 
30 days prior to receiving the first dose of study drug.  
15. Subject has a positive drug and/or alcohol screen at screening or on Day 1 
prior to dosing.  
 
Open-label study methods: 
 
Study design and participants: 
The open-label study of SAGE-217 in MDD was conducted at two sites in the United 
States. IRB approval was obtained at each study site. Sage Therapeutics, Inc. designed 
the trial and collaborated with all investigators in the execution of the trial and collection 
of data. All authors vouch for the accuracy and completeness of the data, data 




The study population included subjects of both sexes, ages 18-65 years, with a 
diagnosis of MDD, and a Hamilton Rating Scale for Depression (HAM-D) total score 
of ≥22. Written informed consent was provided at screening and was required for 
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enrollment.  MDD diagnoses were made using the Structured Clinical Interview for 
Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) Axis I 
Disorders (SCID-I), as performed by a qualified healthcare professional. Key exclusion 
criteria included a history of suicide attempt, history of treatment-resistant depression 
(defined as persistent depressive symptoms despite treatment with adequate doses of 
antidepressants from two different classes for an adequate amount of time [i.e. at least 
4 weeks of treatment]), recent history or active clinically significant manifestations of 
other acute or chronic conditions, positive pregnancy test, history of seizures, medical 
history of bipolar disorder, schizophrenia, and (or) schizoaffective disorder. Subjects 
were allowed to remain on a stable dose of psychotropic medications that were initiated 
at least 14 days prior to screening. Following completion of the treatment period, 
subjects were allowed to begin or alter antidepressant regimens.  
 
Inclusion and exclusion criteria: 
The following inclusion criteria must be met for individuals to be eligible for the study.  
1. Subject has signed an ICF prior to any study-specific procedures being 
performed.  
2. Subject is an ambulatory male or female between 18 and 65 years of age, 
inclusive.  
3. Subject is in good physical health and has no clinically significant findings, as 
determined by the Investigator, on physical examination, 12-lead ECG, or clinical 
laboratory tests.  
4. Subject agrees to adhere to the study requirements.  
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5. Subject has a diagnosis of MDD that has been present for at least a 4-week 
period as diagnosed by Structured Clinical Interview for Diagnostic and Statistical 
Manual of Mental Disorders, Fifth Edition (DSM-5) Axis I Disorders (SCID-I).  
6. Subject has a HAM-D total score of ≥22 at screening and Day 1 (prior to 
dosing).  
7. Removed per Amendment #2.  
8. Subject is willing to delay start of other antidepressant or antianxiety 
medications and any new pharmacotherapy regimens, including as-needed 
benzodiazepine anxiolytics, during the screening and treatment periods.  
9. Subject agrees to practice an acceptable method of highly effective birth 
control at screening and throughout study participation. Highly effective methods 
of birth control include sexual abstinence (for males and females); vasectomy; or 
a condom with spermicide in combination with a highly effective female partner’s 
method (for males); and hormonal methods of contraception (ie, established use 
of oral, implantable, injectable, or transdermal hormones); placement of an 
intrauterine device; placement of an intrauterine system; and mechanical/barrier 
method of contraception (ie, condom or occlusive cap [diaphragm or 
cervical/vault cap] in conjunction with spermicide [foam, gel, film, cream, or 
suppository]) (for females).  
 
Exclusion criteria included:  
Subjects will be excluded if they meet any of the following exclusion criteria.  
1. Subject has a history of suicide attempt.  
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2. Subject has a recent history or active clinically significant manifestations of 
metabolic, hepatic, renal, hematological, pulmonary, cardiovascular, 
gastrointestinal, musculoskeletal, dermatological, urogenital, neurological, or 
eyes, ears, nose, and throat disorders, or any other acute or chronic condition 
that, in the Investigator's opinion, would limit the subject's ability to complete or 
participate in this clinical study.  
3. Subject has a history of treatment-resistant depression, defined as persistent 
depressive symptoms despite treatment with adequate doses of antidepressants 
from two different classes for an adequate amount of time (ie, at least 4 weeks of 
treatment).  
4. Subject has a known allergy to SAGE-217, allopregnanolone, or related 
compounds.  
5. Subject has a positive pregnancy test at screening or on Day 1 prior to the 
start of study drug administration.  
6. Subject has detectable hepatitis B surface antigen (HBsAg), anti-hepatitis C 
virus (HCV), or human immunodeficiency virus (HIV) antibody at screening 
(except if the subject has a documented Hepatitis C antigen test (HCV RNA) with 
a negative result in their recent medical history).  
7. Subject has active psychosis per Investigator assessment.  
8. Subject has a medical history of seizures.  
9. Subject has a medical history of bipolar disorder, schizophrenia, and/or 
schizoaffective disorder.  
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10. Subject has a history of alcohol or drug dependence (including 
benzodiazepines) in the 12 months prior to screening.  
11. Subject has had exposure to another investigational medication or device 
within 30 days prior to screening.  
12. Subject has been treated or randomized in this study (eg, Part A) or any 
other study employing SAGE-217 previously (ie, subject may not have received 
study drug and then re-enroll).  
13. Subject has had administration of psychotropics that have been initiated 
within 14 days prior to screening and/or are not being taken at a stable dose in 
Part A.  
14. Use of any known strong inhibitors and/or inducers of CYP3A4 within the 14 
days or five half-lives (whichever is longer) or consumed grapefruit juice, 
grapefruit, Seville oranges, or St. John's Wort or products containing these within 
30 days prior to receiving the first dose of study drug.  
15. Subject has a positive drug and/or alcohol screen at screening or on Day 1 
prior to dosing  
Procedures: 
Open-label study subjects received an open-label 30 mg dose of SAGE-217 oral 
solution at 8:00PM (± 15 minutes) with food on Days 1 through 14. Subjects remained 
as inpatients during the first 7 days of each study period and per the Investigator’s 
judgment thereafter through Day 15. Treatment follow-up was conducted on an 
outpatient basis and included a follow-up visit at 1 week (21 ±1 day) and at 2 weeks (28 
± 1 day) after the last dose of the study drug.  




The primary endpoint of the open-label study was safety and tolerability.  Safety and 
tolerability were assessed by the frequency and severity of adverse events, vital signs, 
changes in clinical laboratory measures, physical exams, electrocardiograms (ECGs), 
the Stanford Sleepiness Scale (SSS) score, and assessment of suicidality using the 
Columbia-Suicide Severity Rating Scale (C-SSRS). Treatment emergent adverse 
events (TEAEs) were defined as AEs or any worsening of a pre-existing medical 
condition with onset after the start of study drug until 7 days after the last dose. Efficacy 
was assessed by the HAM-D, Montgomery-Åsberg Depression Rating Scale (MADRS), 
and Hamilton Anxiety Rating Scale (HAM-A), including categorical responses, such as 
HAM-D response (≥50% reduction) and HAM-D remission (total score ≤7).  
 
Statistical Analysis: 
Continuous parameters were summarized as n, mean, and standard deviation, with 
categorical variables summarized as frequency counts and percentages.  
 
Open-label study results: 
 
The demographic characteristics are provided in Supplemental Table1 (Table S1). The 
mean age was 48 (12.8) and majority of the patients were female and African American. 
SAGE-217 treatment was generally well tolerated, and there were no serious adverse 
events (SAEs) or discontinuations due to AEs (Table S2). The most common AEs (≥4 
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subjects) were sedation and headache (Table S2). One more AE (tooth abscess) was 
reported in the rest of the follow-up period. 
 
Following treatment with SAGE-217, reduced depressive symptoms were observed at 
Day 15 by the HAM-D total score (the primary efficacy endpoint), with a mean decrease 
from baseline of -19.9 (Supplemental Figure S1).  HAM-D total score reductions were 
present as early as Day 2 and were maintained through the conclusion of the study, two 
weeks after study drug discontinuation (Day 28; Supplemental Figure S1). In 11 of 13 
subjects (85%), the HAM-D total score was reduced by least 50% (HAM-D response) at 
Day 15 compared to baseline, and this HAM-D response was sustained through Day 28 
(Supplemental Figure S2). In 8 of 13 subjects (62%), the HAM-D total score was ≤ 7 at 
the end of the treatment period (HAM-D remission), and remission was sustained 
through Day 28 (Supplemental Figure S2). MADRS scores were consistent with HAM-D 
results, with a mean total decrease from baseline of -26.4 at Day 15 (Supplemental 
Figure S1).  Reduced anxiety symptoms were also observed by the HAM-A, with a 
mean decrease from baseline of -15.5 (Supplemental Figure S1) at Day 15 that was 
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Additional double-blind, randomized, placebo-controlled trial details: 
Bracket Qualification Methodology in the double-blind, randomized, placebo-
controlled trial: 
 
Three categories of services including experience, performance, and 
analysis/remediation were delivered to provide quality rater training and ensure 
consistent ratings throughout the trial. To qualify as a rater for the administration of the 
SCID, HAM-D, HAM-A, MADRS, and CGI, raters had to have advanced degrees (MD, 
DO, or masters level or equivalent in a medical or psychology related field), at least 2 
years of clinical and scale administration experience in major depressive disorder, and 
experience with greater than 5 administrations of SCID, 10 administrations of HAM-D, 
HAM-A, and MADRS, and 20 administrations of CGI in the last 12 months. 
 
CGI-I Response Results in the double-blind, randomized, placebo-controlled trial: 
At Day 15, the percentage of patients who met CGI-I response criteria was greater in 
the SAGE-217 group than in the placebo group (78.6% vs. 45.2%; odds ratio 8.6, 
unadjusted 95% CI, 2.5 to 29.5) (Figure S7; Table S8).  
 
HAM-A Results in the double-blind, randomized, placebo-controlled trial: 
Reductions in anxiety symptoms were also observed favoring SAGE-217 treatment, as 
assessed by the HAM-A. At Day 15, the least squares mean (SE) change from baseline 
in HAM-A total score was -13.2 (1.1)  for the SAGE-217 group and -8.6 (1.1) for the 
placebo group, with an LS mean difference of -4.6 (unadjusted 95% CI, -7.3 to -2.0) 
(Figure S8; Table S9).  
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Supplemental Tables and Figures: 
Supplemental Table 1. Demographics in the open-label study of SAGE-217 in 
MDD.  
Characteristics SAGE-217 (n=13) 
Age (years), mean (SD) 48.0 (12.8) 
Gender   
  Female, n (%) 9 (69.2%) 
Race   
  American Indian or Alaska Native, n (%) 0 
  Asian, n (%) 0 
  Black or African American, n (%) 9 (69.2%) 
Native Hawaiian/Pacific Islander, n (%)  0 
  White, n (%) 4 (30.8%) 
  Other, n (%) 0 
Body Mass Index (kg/m2), mean (SD) 32.2(6.0) 
Baseline HAM-D Score, mean (SD) 27.2 (3.1) 
Baseline Antidepressant use 5 (38.5)  
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Supplemental Table 2. Treatment emergent adverse events (TEAEs) reported by 3 
or more patients in the open-label study of SAGE-217 in MDD, reported as n (%). 
  
TEAEs SAGE-217  
(n=13) 
Patients with at least one TEAE 12 (92.3%) 
Patients with serious AEs 0 
Patients with severe AEs 0 
TEAEs reported by 3 or more patients  
Sedation 6 (46.2%) 
Headache 4 (30.8%) 
Dizziness 3 (23.1%) 
Somnolence 3 (23.1%) 
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Supplemental Table 3:  Duration of prior antidepressant therapy in patients receiving 
antidepressant therapy in the double-blind randomized, placebo-controlled trial.  






<8 weeks 0 0 
2-6 months 5 (50) 3 (25) 
6-12 months 0 2 (17) 
12-24 months 1 (10) 4 (24) 
24-48 months 1 (10) 2 (17) 
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Supplemental Table 4. Results from the sensitivity analyses on the primary 
endpoint at Day 15, based on two different imputation methods: multiple 
imputation (using a fully conditional specification regression method) and last 
observation carried forward (using the last observed non-missing value). 
 
 









95% CI p-value 
Primary model -17.4 (1.3) -10.3 (1.3) -7.0 (1.6) -10.2 to -3.9 <0.001 
Multiple 




carried forward -17.2 (1.3) -10.3 (1.3) -6.9 (1.6) 
-10.1 to -
3.7 <0.001 
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Supplemental Table 5: HAM-D total score, response, and remission statistics in the double-blind, randomized 
trial of SAGE-217. HAM-D total score least-squares (LS) means were calculated using a mixed effects model for 
repeated measures (MMRM). HAM-D response and remission were analyzed using generalized estimating equation 
(GEE) models. LS means are presented with standard errors (SE).  The widths of the confidence intervals have not been 
adjusted for multiplicity, so the intervals should not be used to infer definitive treatment effects for secondary outcomes 
(i.e. HAM-D Total Score changes on Days 2-8, 21, 28, 35, 42; HAM-D Response and Remission). 
  HAM-D Total Score 
  
  HAM-D Response HAM-D Remission 












Ratio 95% CI 
Day 2 -5.8 (0.97) -3.5 (0.98) -2.3 (0.99) -4.3 to -0.3 16% 5% 4.4 0.8 to 24.1 2% 0% N/A N/A 
Day 3 -9.3 (1.07) -5.2 (1.09) -4.1 (1.18) -6.4 to -1.7 33% 9% 6.8 1.9 to 23.8 13% 2% 6.8 0.8 to 61.8 
Day 4 -10.6 (1.11) -7.7 (1.13) -2.9 (1.27) -5.5 to -0.4 40% 26% 2.5 0.9 to 6.8 16% 7% 2.6 0.6 to 11.3 
Day 5 -12.3 (1.17) -8.5 (1.19) -3.8 (1.37) -6.6 to -1.1 58% 32% 4.5 1.7 to 11.9 16% 14% 1.2 0.4 to 3.9 
Day 6 -13.6 (1.19) -9.1 (1.21) -4.5 (1.40) -7.3 to -1.7 64% 39% 4.6 1.7 to 12.0 38% 14% 3.9 1.3 to 11.4 
Day 7 -13.7 (1.27) -9.2 (1.29) -4.5 (1.53) -7.6 to -1.5 60% 42% 3.3 1.2 to 8.9 33% 14% 3.2 1.1 to 9.4 
Day 8 -14.4 (1.27) -11.0 (1.29) -3.4 (1.54) -6.4 to -0.3 59% 48% 2.4 0.9 to 6.4 36% 29% 1.5 0.6 to 3.7 
Day 15 -17.4 (1.31) -10.3 (1.33) -7.0 (1.60) -10.2 to -3.9 79% 41% 9.6 2.9 to 31.6 64% 26% 5.3 2.1 to 13.3 
Day 21 -16.3 (1.40) -11.3 (1.43) -4.9 (1.76) -8.4 to -1.4 74% 42% 6.7 2.3 to 19.7 52% 26% 3.1 1.2 to 8.0 
Day 28 -15.4 (1.41) -11.3 (1.44) -4.1 (1.77) -7.6 to -0.5 62% 46% 3.1 1.1 to 8.9 52% 28% 2.9 1.2 to 7.3 
Day 35 -14.9 (1.47) -12.6 (1.49) -2.3 (1.86) -6.0 to 1.4 66% 50% 3 1.0 to 9.0 44% 35% 1.4 0.6 to 3.5 
Day 42 -14.6 (1.46) -12.3 (1.49) -2.3 (1.86) -6.0 to 1.4 62% 56% 1.9 0.7 to 5.6 45% 33% 1.7 0.7 to 4.3 
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Supplemental Table 6. Day 15 HAM-D total score mean change from baseline, 
HAM-D response (≥50% reduction in total score), and HAM-D remission (total score 
≤7) stratified by concomitant antidepressant use during the treatment period in 
the double-blind, randomized, placebo-controlled study. This is a post-hoc 
descriptive analysis, and no statistical inferences can be made from the data. 










Number of patients with 
available HAM-D total 
score at Day 15 
 
 
9 12 33 30 
HAM-D Change from 
Baseline, mean (SD) 
 
-7.7 (7.0) -17.9 (8.1) -11.6 (7.9) -17.5 (7.2) 
HAM-D Response, n (%) 
 
2 (22.2%) 10 (83.3%) 15 (45.5%) 23 (76.7%) 
HAM-D Remission, n (%) 
 
1 (11.1%) 8 (66.7%) 10 (30.3%) 19 (63.3%) 
 
  Gunduz-Bruce et al., 2018 
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Supplemental Table 7. Number of patients who received additional 
antidepressants in the naturalistic follow-up period in the double-blind, 






Placebo 33 11 





  Gunduz-Bruce et al., 2018 
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Supplemental Table 8. Montgomery-Åsberg Depression Rating Scale 
(MADRS) change over time in the double-blind, randomized, placebo-
controlled study. MADRS total scores were recorded as indicated across 42 
days. The change from baseline in MADRS total score least squares (LS) means 
was determined by a mixed model for repeated measures. LS means are 
presented with standard errors (SE).  SAGE-217, n=45; Placebo, n=44. The 
widths of the confidence intervals have not been adjusted for multiplicity, so the 
intervals should not be used to infer definitive treatment effects for secondary 
outcomes. 
Day Placebo (n=44) SAGE-217 (n=45) LS Mean Difference 95% CI 
2 -4.5 (1.4) -6.9 (1.4) -2.4 (1.4) -5.1 to 0.3 
3 -7 (1.5) -11.8 (1.5) -4.8 (1.6) -8.0 to -1.5 
4 -9.8 (1.6) -14 (1.6) -4.2 (1.8) -7.8 to -0.6 
5 -11.6 (1.7) -15.6 (1.7) -4.0 (2.0) -7.9 to 0.0 
6 -12.9 (1.7) -17.8 (1.6) -4.9 (1.9) -8.7 to -1.1 
7 -13.3 (1.9) -18.0 (1.9) -4.7 (2.3) -9.2 to -0.2 
8 -15.4 (1.9) -19.4 (1.9) -4.0 (2.3) -8.6 to 0.6 
15 -15 (1.9) -22.5 (1.9) -7.6 (2.4) -12.3 to -2.8 
21 -15.2 (2.1) -21.9 (2.1) -6.6 (2.7) -12.0 to -1.3 
28 -14.8 (2.1) -20.1 (2.1) -5.3 (2.7) -10.6 to 0.1 
35 -16.4 (2.3) -19.4 (2.2) -3.1 (2.9) -8.8 to 2.6 







  Gunduz-Bruce et al., 2018 
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Supplemental Table 9:  CGI-I Response in the double-blind, randomized, 
placebo-controlled study. CGI-I response was considered a score of 1 (very 
much improved) or 2 (much improved) and was analyzed using a generalized 
estimating equation model. SAGE-217, n=45; Placebo, n=44.  The widths of the 
confidence intervals have not been adjusted for multiplicity, so the intervals 
should not be used to infer definitive treatment effects for secondary outcomes.  
Day Placebo (n=44) SAGE-217 (n=45) Odds Ratio 95% CI 
3 7% 40% 16.9 3.5 to 81.5 
8 45% 70% 5.5 1.7 to 17.9 
15 45% 79% 8.6 2.5 to 29.5 
21 50% 71% 4.4 1.4 to 13.6 
28 46% 67% 3.9 1.2 to 12.8 
35 55% 63% 2.3 0.7 to 7.2 
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Supplemental Table 10. HAM-A in the double-blind, randomized, 
placebo-controlled study. HAM-A total scores were recorded as indicated 
across 42 days. The change from baseline in HAM-A total score least squares 
(LS) means was determined by a mixed model for repeated measures. LS 
means are presented with standard errors (SE).  SAGE-217, n=45, Placebo, 
n=44. The widths of the confidence intervals have not been adjusted for 
multiplicity, so the intervals should not be used to infer definitive treatment effects 
for secondary outcomes.  
 
Day Placebo (n=44) SAGE-217 (n=45) LS Means Difference 95% CI 
2 -3.7 (0.9) -5.5 (0.8) -1.8 (0.9) -3.6 to -0.1 
3 -5.7 (0.9) -8.3 (0.9) -2.6 (1.0) -4.6 to -0.6 
8 -8.9 (1.1) -11.4 (1.1) -2.5 (1.3) -5.1 to 0.0 
15 -8.6 (1.1) -13.2 (1.1) -4.6 (1.3) -7.3 to -2.0 
21 -9.5 (1.3) -12.9 (1.21) -3.4 (1.5) -6.5 to -0.4 
28 -10.0 (1.3) -12.2 (1.2) -2.2 (1.6) -5.3 to 0.9 
35 -9.9 (1.4) -12.0 (1.4) -2.0 (1.8) -5.5 to 1.5 
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Supplemental Table 11. Adverse events (AEs) reported after the treatment-
emergent period (Days 21-42). Data are presented as n (%), as indicated. 
 
SAGE-217 Placebo Total 
  n=45 n=44 n=89 
 n (%) n (%) n (%) 
Patients with at least one AE 4 (8.9) 10 (22.7) 14 (15.7) 
Patients with serious AEs 0 0 0 
Patients with severe AEs 0 0 0 
AEs after the treatment emergent period 
Headache 1 (2.2) 1 (2.3) 2 (2.2) 
Nausea 0 2 (4.5) 2 (2.2) 
Upper respiratory tract infection 0 2 (4.5) 2 (2.2) 
Blood pressure increased 1 (2.2) 0 1 (1.1) 
Diarrhea 0 1 (2.3) 1 (1.1) 
Flank Pain 0 1 (2.3) 1 (1.1) 
Hypothyroidism 1 (2.2) 0 1 (1.1) 
Laceration 1 (2.2) 0 1 (1.1) 
Myalgia 0 1 (2.3) 1 (1.1) 
Oropharyngeal pain 0 1 (2.3) 1 (1.1) 
Rhinitis 0 1 (2.3) 1 (1.1) 
Sexual dysfunction 0 1 (2.3) 1 (1.1) 
Viral infection 0 1 (2.3) 1 (1.1) 
Vomiting 0 1 (2.3) 1 (1.1) 
  
  Gunduz-Bruce et al., 2018 
 
27 | P a g e  
 
Supplemental Table 12.  Stanford sleepiness scale (SSS)  
The SSS is subject-rated scale designed to quickly assess how alert a subject is 
feeling. Degrees of sleepiness and alertness are rated on a scale of 1 to 7, where 
the lowest score of ‘1’ indicates the subject is ‘feeling active, vital, alert, or wide 
awake’, the highest score of ‘7’ indicates the subject is ‘no longer fighting sleep, 
sleep onset soon; having dream-like thoughts’ and X indicates “Asleep”. No 
scores of “X” were recorded. SAGE-217, n=45; Placebo, n=44. The mean (SD) 
values are presented.  
 Time Point Placebo (n=44) SAGE-217 (n=45) 
Baseline  2.7 (1.5) 2.6 (1.3) 
Day 1 1 hour postdose 2.6 (1.4) 2.7 (1.3) 
 2 hours postdose 2.6 (1.4) 3.1 (1.5) 
Day 7 Predose 1.9 (0.8) 2.0 (1.0) 
 1 hour postdose 2.2 (1.1) 2.4 (1.2) 
 2 hours postdose 2.4 (1.3) 2.7 (1.2) 
Day 14 Predose 2.0 (0.8) 2.0 (1.2) 
 1 hour postdose 2.1 (1.0) 2.3 (1.3) 
Day 15  2.2 (1.1) 1.8 (1.2) 
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Supplemental Table 13.  Treatment emergent adverse events (TEAEs) 
reported by 3 or more patients in the double-blind, randomized, placebo-





SAGE-217 - no 
antidepressant 
(n=33) 
Any TEAE 8 (66.7%) 16 (48.5%) 
Headache 3 (25.0%) 5 (15.2%) 
Dizziness 1 (8.3%) 4 (12.1%) 
Nausea 2 (16.7%) 3 (9.1%) 
Somnolence 2 (16.7%) 1 (3.0%) 
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Supplemental Figure 1. HAM-D, MADRS, and HAM-A total scores in an 
open-label study of SAGE-217 in MDD. A. HAM-D total scores were recorded 
as indicated across 28 days.  The change from baseline in HAM-D total score 
least squares (LS) means was determined by a mixed model for repeated 
measures. Error bars are SE.  B. MADRS total scores were recorded as 
indicated across 28 days. The change from baseline in MADRS total score least 
squares (LS) means was determined by a mixed model for repeated measures. 
Error bars are SE.  C. HAM-A total scores were recorded as indicated across 28 
days. The change from baseline in HAM-A total score least squares (LS) means 
was determined by a mixed model for repeated measures. Error bars are SE. 
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Supplemental Figure 2. HAM-D Response and HAM-D Remission Rates in 
the open-label study of SAGE-217 in MDD. HAM-D response was defined as a 
≥50% decrease from the baseline HAM-D total score. HAM-D remission was 
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Supplemental Figure 3. HAM-D change from baseline, HAM-D response, 
and HAM-D remission up to Day 42 in the double-blind, randomized, 
placebo-controlled study. A. The change from baseline in HAM-D least 
squares (LS) means was determined by a mixed model for repeated measures.  
Error bars are SE.  B. HAM-D response was defined as a reduction from 
baseline HAM-D total score of 50% or greater and was evaluated using a 
generalized estimating equation model. C. HAM-D remission was defined as a 
HAM-D total score of 7 or less and was evaluated using a generalized estimating 
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Supplemental Figure 4. Bech-6 subscale change from baseline in the 
double-blind, randomized, placebo-controlled study. Least squares (LS) 
mean Bech-6 scores were calculated at each time point using a mixed model for 
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Supplemental Figure 5.  Improvements in the items of the Bech-6 subscale 
in the double-blind, randomized, placebo-controlled study at the primary 
endpoint, Day 15. The individual items comprising the Bech-6 subscale of the 
HAM-D were analyzed by a mixed model for repeated measures. LS mean 
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Supplemental Figure 6. Montgomery-Åsberg Depression Rating Scale 
(MADRS) change over time in the double-blind, randomized, placebo-
controlled study. MADRS total scores were recorded as indicated across 42 
days. The change from baseline in MADRS total score least squares (LS) means 
was determined by a mixed model for repeated measures. Error bars are SE. 
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Supplementary Figure 7. CGI-I Response in the double-blind, randomized, 
placebo-controlled study. CGI-I response was considered a score of 1 (very 
much improved) or 2 (much improved) and was analyzed using a generalized 
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Supplemental Figure 8. HAM-A in the double-blind, randomized, placebo-
controlled study. HAM-A total scores were recorded as indicated across 42 
days. The change from baseline in HAM-A total score least squares (LS) means 
was determined by a mixed model for repeated measures. Error bars are SE. 
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